262 related articles for article (PubMed ID: 9252738)
21. Clobetasol propionate shampoo 0.05% is efficacious and safe for long-term control of moderate scalp psoriasis.
Poulin Y; Papp K; Bissonnette R; Barber K; Kerrouche N; Villemagne H;
J Dermatolog Treat; 2010 May; 21(3):185-92. PubMed ID: 20131980
[TBL] [Abstract][Full Text] [Related]
22. Clobetasol propionate spray 0.05% add-on therapy to a stable regimen of biologic treatment in patients with moderate to very severe plaque psoriasis.
Feldman SR; Koo JY; Johnson LA; Preston NJ
Cutis; 2009 Oct; 84(4 Suppl):25-32. PubMed ID: 19916299
[TBL] [Abstract][Full Text] [Related]
23. Halobetasol 0.01% Lotion in the Treatment of Moderate-to-Severe Plaque Psoriasis of the Lower Extremities.
Bhatia ND; Vlahovic TC; Green LG; Martin G; Lin T
J Drugs Dermatol; 2019 Oct; 18(10):1029-1036. PubMed ID: 31584782
[TBL] [Abstract][Full Text] [Related]
24. The use of 0.25% zinc pyrithione spray does not enhance the efficacy of clobetasol propionate 0.05% foam in the treatment of psoriasis.
Housman TS; Keil KA; Mellen BG; McCarty MA; Fleischer AB; Feldman SR
J Am Acad Dermatol; 2003 Jul; 49(1):79-82. PubMed ID: 12833013
[TBL] [Abstract][Full Text] [Related]
25. Efficacy and safety of fluticasone propionate ointment, 0.005%, in the treatment of eczema.
Lebwohl M
Cutis; 1996 Feb; 57(2 Suppl):62-8. PubMed ID: 8646873
[TBL] [Abstract][Full Text] [Related]
26. Short- and long-term safety assessment of a two-compound ointment containing calcipotriene/betamethasone dipropionate (Taclonex/Daivobet/Dovobet ointment): hypothalamic-pituitary-adrenal axis function in patients with psoriasis vulgaris.
Fleming C; Ganslandt C; Leese GP
J Drugs Dermatol; 2010 Aug; 9(8):969-74. PubMed ID: 20684147
[TBL] [Abstract][Full Text] [Related]
27. Twice weekly fluticasone propionate added to emollient maintenance treatment to reduce risk of relapse in atopic dermatitis: randomised, double blind, parallel group study.
Berth-Jones J; Damstra RJ; Golsch S; Livden JK; Van Hooteghem O; Allegra F; Parker CA;
BMJ; 2003 Jun; 326(7403):1367. PubMed ID: 12816824
[TBL] [Abstract][Full Text] [Related]
28. Improvement in signs and symptoms of plaque psoriasis after 1 week of treatment with clobetasol propionate 0.05% spray.
Brodell R; Preston N
J Drugs Dermatol; 2012 Dec; 11(12):1455-9. PubMed ID: 23377516
[TBL] [Abstract][Full Text] [Related]
29. A phase 2, multicenter, double-blind, randomized, vehicle-controlled clinical study to compare the safety and efficacy of a halobetasol propionate 0.01% lotion and halobetasol propionate 0.05% cream in the treatment of plaque psoriasis.
Kerdel FA; Draelos ZD; Tyring SK; Lin T; Pillai R
J Dermatolog Treat; 2019 Jun; 30(4):333-339. PubMed ID: 30207807
[No Abstract] [Full Text] [Related]
30. Halobetasol Propionate Lotion 0.01% for Moderate-to-Severe Plaque Psoriasis: Pooled Analysis in Male and Female Participants.
Cook-Bolden FE; Hebert AA; Guenthner ST; Kang R; Martin G; Jacobson A
J Drugs Dermatol; 2020 Aug; 19(8):747-754. PubMed ID: 32845589
[TBL] [Abstract][Full Text] [Related]
31. Halobetasol 0.01%/Tazarotene 0.045% Lotion in the Treatment of Moderate-to-Severe Plaque Psoriasis: Maintenance of Therapeutic Effect After Cessation of Therapy.
J Drugs Dermatol; 2019 Aug; 18(8):815-820. PubMed ID: 31424713
[TBL] [Abstract][Full Text] [Related]
32. Comparison of clinical efficacy of topical tazarotene 0.1% cream with topical clobetasol propionate 0.05% cream in chronic plaque psoriasis: a double-blind, randomized, right-left comparison study.
Angelo JS; Kar BR; Thomas J
Indian J Dermatol Venereol Leprol; 2007; 73(1):65. PubMed ID: 17319037
[TBL] [Abstract][Full Text] [Related]
33. Halobetasol 0.01%/Tazarotene 0.045% Lotion in the Treatment of Moderate-to-Severe Plaque Psoriasis: Maintenance of Therapeutic Effect After Cessation of Therapy.
Pariser DM; Green LJ; Stein Gold L; Sugarman JL; Lin T; Pillai R
J Drugs Dermatol; 2018 Jul; 17(7):723-726. PubMed ID: 30005093
[TBL] [Abstract][Full Text] [Related]
34. The evolving role of topical treatments in adjunctive therapy for moderate to severe plaque psoriasis.
Lebwohl M; Colón LE
Cutis; 2007 Nov; 80(5 Suppl):29-40. PubMed ID: 18154221
[TBL] [Abstract][Full Text] [Related]
35. [Assessment of value and risks of external treatment with clobetasol-17-propionate (Dermovate)].
van der Harst LC; Smeenk G; Burger PM; van der Rhee HJ; Polano MK
Ned Tijdschr Geneeskd; 1978 Feb; 122(7):219-23. PubMed ID: 345134
[No Abstract] [Full Text] [Related]
36. A randomized, investigator-masked clinical evaluation of the efficacy and safety of clobetasol propionate 0.05% shampoo and tar blend 1% shampoo in the treatment of moderate to severe scalp psoriasis.
Griffiths CE; Finlay AY; Fleming CJ; Barker JN; Mizzi F; Arsonnaud S
J Dermatolog Treat; 2006; 17(2):90-5. PubMed ID: 16766333
[TBL] [Abstract][Full Text] [Related]
37. Two Multicenter, Randomized, Double-Blind, Parallel Group Comparison Studies of a Novel Enhanced Lotion Formulation of Halobetasol Propionate, 0.05% Versus Its Vehicle in Adult Subjects With Plaque Psoriasis.
Pariser D; Bukhalo M; Guenthner S; Kempers S; Shideler S; Gold LS; Tschen E; Berg J; Ferdon MB; Dromgoole S
J Drugs Dermatol; 2017 Mar; 16(3):234-240. PubMed ID: 28301619
[TBL] [Abstract][Full Text] [Related]
38. Safety and Efficacy of a Once-Daily Halobetasol Propionate 0.01% Lotion in the Treatment of Moderate-to-Severe Plaque Psoriasis: Results of Two Phase 3 Randomized Controlled Trials.
Green LJ; Kerdel FA; Cook-Bolden FE; Bagel J; Lin T; Martin G; Pillai R; Israel R; Ramakrishna T
J Drugs Dermatol; 2018 Oct; 17(10):1062-1069. PubMed ID: 30365586
[TBL] [Abstract][Full Text] [Related]
39. Clobetasol propionate 0.05% in a novel foam formulation is safe and effective in the short-term treatment of patients with delayed pressure urticaria: a randomized, double-blind, placebo-controlled trial.
Vena GA; Cassano N; D'Argento V; Milani M
Br J Dermatol; 2006 Feb; 154(2):353-6. PubMed ID: 16433809
[TBL] [Abstract][Full Text] [Related]
40. Comparing clobetasol propionate 0.05% spray to calcipotriene 0.005% betamethasone dipropionate 0.064% ointment for the treatment of moderate to severe plaque psoriasis.
Menter A; Abramovits W; Colón LE; Johnson LA; Gottschalk RW
J Drugs Dermatol; 2009 Jan; 8(1):52-7. PubMed ID: 19180896
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
